Skip to content
TickerMagic

Venus Remedies Limited

VENUSREMNSEHealthcare
₹1,501.6
+46.60 (+3.20%) · EOD 2026-11-20

Our verdict

Strong Buy

Financial trend (100/100) does the heavy lifting; momentum (34/100) is the drag.

Buy zoneHealth A
Quality 75Momentum 34Value 91Trend 100The Spark ↓

Our fair value

Undervalued by 79%
₹2,683.89up 78.74%
Price ₹1,502Range ₹801 – ₹3,003

Buy-below (20% margin of safety): ₹2,147.11

The bottom line

Venus Remedies Limited earns a Strong Buy from TickerMagic, with a blended score of 77/100. At ₹1,501.6 it trades below our blended DCF and relative-multiples fair value of ₹2,683.89, about 79% upside to that estimate — we read it as undervalued by 79%. On 19.0x trailing earnings it sits cheaper than the Healthcare median of about 37.4x. The price is about 22% below its 52-week high of ₹1,934.54 and 132% above the low of ₹647.28. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 6/9. It clears 9 of 11 investability checks, with durability 75, valuation 82 and momentum 34 on our 0–100 scales.

Analysis by Ankit Sharma · TickerMagic's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.

Intrinsic value
Our fair value
₹2,683.89up 78.74%
Undervalued by 79%
Price ₹1,501.6Range ₹801.11–₹3,003.2
DCF + relative blendmedium confidence

With a 20% margin of safety, our buy-below price is ₹2,147.11.

1-year price

EOD · 2026-11-20
1D
up 3.20%
1W
up 3.95%
1M
down 5.75%
3M
down 17.47%
6M
up 50.35%
1Y
—

52-week range

-22.38% from the 52-week high.

Trend check
Below 50-DMA₹1,550Above 200-DMA₹1,324

Price above both moving averages reads as an intact uptrend; below both, the trend is against you.

Verdict pillars

Strong Buy77
A
Financial health 100/100
Altman Z 8.27 · Safe zone

Piotroski F-score 6/9 — quality of earnings & balance sheet.

Our scores

Durability75
Valuation82
Momentum34

Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.

Investability checklist

Passed 9 of 11 checks
Each check screens one fundamentals, valuation or trend signal.
  • No data: ROE above 15%
  • Pass: Low debt (D/E < 0.5): 0.02x
  • Pass: Positive free cash flow
  • Pass: Revenue growth > 10%: 36%
  • Pass: Earnings growing: 139%
  • Pass: Net margin ≥ 10%: 14.3%
  • No data: Current ratio > 1.5
  • Pass: Below our fair value
  • Pass: Margin of safety ≥ 20%
  • Pass: Above 200-day average
  • Fail: Above 50-day average
  • No data: Positive 1-year return
  • Pass: Altman Z in safe zone: Z 8.27
  • Fail: Piotroski ≥ 7: 6/9

Shareholding

  • Promoter48.6%
  • Institutions1.2%
  • Public & other50.2%

Promoter holding via insider stake; institutional via reported holdings.

Key fundamentals

Market cap
₹2,207 Cr
P/E ratio
19.0
P/B ratio
3.32
EPS (TTM)
₹86.92
ROE
—
Debt / Equity
0.02x
Profit margin
14.3%
Free cash flow
₹118 Cr
52-week high
₹1,934.54
-22.38% from high
52-week low
₹647.28
Dividend yield
0.6%
Beta
0.25
SWOT snapshot

Bull case vs bear case

Bull case

Strengths

  • Lightly leveraged balance sheet.
  • Financially solid — Altman Z 8.27.

Opportunities

  • Earnings growing (139% YoY).
  • Revenue growing (36% YoY).
  • Trading in our value buy zone versus sector peers.
  • Trades ~79% below our estimated fair value.

About Venus Remedies Limited

Venus Remedies Limited operates as a pharmaceutical company in India and internationally, with research and development focused on antimicrobial resistance and oncology. The company manufactures and offers a broad range of medications including analgesics, antipyretics, antibiotics, anticoagulants, antiemetics, antivirals, cardiovascular drugs, disinfectants, antiseptics, gastrointestinal therapies, hepatoprotective agents, steroids, immunostimulating agents, iron supplements, and muscle relaxants.

Venus Remedies Limited — frequently asked questions

Is Venus Remedies Limited a buy, hold or sell?

TickerMagic currently rates Venus Remedies Limited (VENUSREM) a Strong Buy, based on a blended score of 77/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.

What is Venus Remedies Limited's fair value?

Our blended DCF and relative-valuation model estimates Venus Remedies Limited's fair value at about ₹2,683.89, versus a current price of ₹1,501.6 — roughly 79% upside. On that basis the stock looks undervalued by 79%.

Is Venus Remedies Limited financially healthy?

Venus Remedies Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 6/9.

How has Venus Remedies Limited's share price performed?

Venus Remedies Limited is down 17% over three months, and last traded at ₹1,501.6. Past performance doesn't predict future returns.

Our verdict, fair value, financial-health and checklist are TickerMagic's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.